Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Celiprolol in hypertension.

S H Taylor1

  • 1University Department of Cardiovascular Studies and Medical, Department of Cardiology, General Infirmary, Leeds, United Kingdom.

American Heart Journal
|November 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maximal stomatal conductance to water and plasticity in stomatal traits differ between native and invasive introduced lineages of Phragmites australis in North America.

AoB PLANTS·2016
Same author

Photosynthetic pathway and ecological adaptation explain stomatal trait diversity amongst grasses.

The New phytologist·2011
Same author

Drought limitation of photosynthesis differs between C₃and C₄grass species in a comparative experiment.

Plant, cell & environment·2010
Same author

Effects of chronic hepatitis C infection on the treatment of breast cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2009
Same author

Efficacy and tolerability of amlodipine in the general practice treatment of essential hypertension in an asian multinational population.

Clinical drug investigation·2008
Same author

Social work practice with people with disabilities in the era of disability rights.

Social work in health care·2001
Same journal

Stratified Medicine with Eplerenone for Myocardial Infarction or Injury and No obstructive Coronary Arteries: A Registry-Based Basket Trial.

American heart journal·2026
Same journal

Revised Lipid-Lowering Therapy Guidelines in a Nationally Representative Sample.

American heart journal·2026
Same journal

Cardiometabolic Health of Low- and Higher-Income Adults in the United States, 2009-2023.

American heart journal·2026
Same journal

Moving Beyond Technical Capability to Regulatory Integration for Digital Health Technology Devices-Brief Communication from the Cardiovascular Sciences Research Consortium.

American heart journal·2026
Same journal

THE SOCIETY OF CRITICAL CARE CARDIOLOGY - RATIONALE, BLUEPRINT, AND LESSONS LEARNED IN THE CREATION OF A NEW MULTIDISCIPLINARY PROFESSIONAL ORGANIZATION.

American heart journal·2026
Same journal

DOAC Score Among Patients Receiving Vitamin K Antagonists.

American heart journal·2026
See all related articles

Celiprolol, a third-generation beta-blocker, effectively manages hypertension for 24 hours. It offers benefits beyond standard beta-blockade, including improved cardiovascular risk factors.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Hypertension management requires effective and safe therapeutic options.
  • Third-generation beta-blockers offer potential advantages over older agents.
  • Celiprolol possesses unique ancillary pharmacologic properties.

Purpose of the Study:

  • To evaluate the efficacy and safety of celiprolol in treating hypertension.
  • To compare celiprolol's effects with placebo, other beta-blockers, and enalapril.
  • To assess celiprolol's impact on cardiovascular risk factors.

Main Methods:

  • Clinical trials were conducted to assess blood pressure control.
  • Comparative efficacy studies were performed against placebo, beta-blocking drugs, and enalapril.
  • Analysis included effects on exercise-induced blood pressure and heart rate changes.

Related Experiment Videos

  • Impact on cholesterol, triglyceride, and fibrinogen levels was investigated.

    • Main Results:

    • Celiprolol demonstrated 24-hour blood pressure control.
    • It was superior to placebo and comparable in efficacy to other beta-blockers.
    • Celiprolol showed equal efficacy to enalapril in lowering resting blood pressure.
    • It was superior to enalapril in controlling exercise-induced blood pressure and heart rate.
    • Beneficial effects on atheroprotective factors like cholesterol, triglycerides, and fibrinogen were observed.

    Conclusions:

    • Celiprolol is an effective antihypertensive agent with a favorable 24-hour profile.
    • Its ancillary properties enhance traditional beta-blockade, offering broader cardiovascular benefits.
    • Celiprolol presents a valuable therapeutic option for hypertension, particularly with associated cardiovascular risk factors.